Adjuvants are not active ingredients for the purposes of SPC protection - .PDF file.
The Court of Justice of the European Union (CJEU) has released a ‘reasoned order’ in the GSK Biologicals SA case (C-210/13). The conclusion is that an adjuvant to a vaccine is not an active ingredient and so a vaccine/adjuvant combination is not a product capable of SPC protection…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.